CHANGES IN THE CONTENT OF IMMUNE CELLS CONTAINING THE FcR III RECEPTOR IN THE SLEEP AND BRAIN AFTER EXPERIMENTAL TBI

Abstract

At TBI there are disturbances in activity of immune system, can complicate regenerative and reparative responses in a brain. The aim of the study was to study the content of CD-16 cells in the spleen and brain parenchyma at different times after TBI in rats and in the correction of disorders in their composition by immunomodulatory drug galalite.Methods. Craniocerebral trauma in animals was modeled by dropping a load weighing 100 g from a height of 120 cm on the head of rats that were anesthetized and were in a state of narcotic sleep, which lasted up to 30 minutes. To correct the resulting disorders used immunomodulatory drug galavit at a dose of 2 mg / kg of animal weight in a volume of0.5 ml, which was administered intramuscularly to animals for 2, 3, 4 days after injury. The spleen and the left and right hemispheres of the brain were homogenized in 5.0 ml of medium 199 and suspensions containing 10.0x106 cells per 1 ml of medium 199 microglia were prepared and infiltrated CNS monocytes were prepared by the method of Sedgwick J. in co-authors. Determination of the level of CD-16 cells in suspensions of spleen and microglia was performed on a flow cytometer using monoclonal antibodies against CD-16 receptor company BD Biosciences according to the instructions for antibodies.Results. In mild TBI in rats, the number of CD- 16 cells containing the FcR III receptor decreases in the spleen for 2 to 5 days, and the number of these cells in the fractions of microglial cells increases. Galavit is a drug with immunomodulatory properties, has virtually no effect on low levels of CD-16 cells in the spleen and stimulates their accumulation in the brain for 10 days after TBI.Conclusions. The results indicate the effect of Galavit on the level of CD-16 cells in the spleen and brain, which indicates the immunomodulatory activity of this drug.